Double-blind randomized controlled study of the efficacy, safety and tolerability of eszopiclone vs placebo for the treatment of patients with post-traumatic stress disorder and insomnia

Table 1 Baseline demographic and clinical characteristics of patient (n = 25)

Characteristics	Eszopiclone	Placebo	Total sample
	(n = 13)	(n = 12)	(n = 25)
Age, mean ± SD	38 ± 11.6	48 ± 11.3	43 ± 12.2
Sex, male, n (%)	8 (54)	7 (58)	15 (60)
Race, n (%)
White	4	2	6 (24)
African American	7	7	14 (56)
Hispanic	1	1	2 (8
Mixed	1	2	3 (12)
Education status, college graduate, n (%)	5	4	9 (36)
Duration of illness in years, mean ± SD	5 ± 7	7 ± 8	6 ± 8
Current comorbidity, n (%)
Major depressive disorder	7	7	14
Social anxiety disorder	2	1	3
Generalized anxiety disorder	0	1	1
Lifetime depression, n	8	9	17
Lifetime alcohol or substance abuse or dependency, n	8	3	11
Concomitant antidepressant, n	0	2	2
Concomitant benzodiazepine, n	0	1	1
Drop-outs	6	3	9